newsfilter
← Latest News
GlobeNewswire·

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023

-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no safety signal